The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    March 2020

  • Pages
    318

  • View Count
    14643

Example Insights

Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Context Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Clinical Research Landscape Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - List of Manufacturers
Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Manufacturers Landscape Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Manufacturer Locations Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Competitiveness Analysis
Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Recent Expansions Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Capacity Analysis Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Demand vs. Supply
Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Market Forecast Oligonucleotide Synthesis, Modification and Purification Services Market, 2020-2030 - Opportunity Analysis

 

Overview

Oligonucleotides have a wide range of applications in medical science. In basic research and diagnostics, these are indispensable to contemporary molecular testing and analytical protocols (such as the polymerase chain reaction (PCR), and DNA sequencing), genomic library construction and artificial gene synthesis. In fact, amid the ongoing coronavirus pandemic, several oligonucleotide manufacturers have started offering critical oligonucleotide chemistries, controls and components for the delivery of COVID-19 detection kits at scale. As therapeutic agents, oligonucleotides are known to be associated with certain unique features, such as high selectivity and potency (similar to biologics), and differentiated pharmacology, which further augment their drug-like properties. Moreover, there are established rational approaches that can be leveraged to design oligonucleotide leads, and the overall cost of such drug development initiatives, compared to conventional small molecule drugs and biologics, is reportedly lower. Vitravene® was the first antisense oligonucleotide-based product in 1998. At present, eight oligonucleotide-based drugs are available in the market, namely (in reverse chronological order of year of approval) GIVLAARI™ (2019), ONPATTRO® (2018), TEGSEDI™ (2018), SPINRAZA® (2016), EXONDYS 51® (2016), DEFITELIO® (2016), KYNAMRO™ (2013), and MACUGEN® (2004). Further, more than 200 unique oligonucleotide-based product candidates are currently being evaluated in various preclinical / clinical phases of development.

According to experts, the use of oligonucleotides as a treatment option is limited due to complexities associated with the synthesis of such compounds. Similar to small molecule drugs, oligonucleotides can be manufactured via chemical synthesis methods, solid phase synthesis being one of the most popular approaches used. However, there are certain technical requirements (chemical modification-related expertise) and complex analytical expertise required for development, synthesis and purification of this class of molecules. As a result, oligonucleotide manufacturing has emerged as a much sought-after capability within the modern biopharmaceutical industry. Presently, a significant proportion of the existing expertise and manufacturing capacity for oligonucleotides belong to contract service providers. In fact, most researchers and many therapy / diagnostic developers have demonstrated preference to outsource oligonucleotide manufacturing operations, instead of building in-house capabilities for the same. Several big pharma companies, despite having proprietary manufacturing capabilities, are known to outsource more than half of their clinical stage oligonucleotide manufacturing operations. In the foreseen future, we anticipate the demand and opportunities for contract manufacturing organizations (CMO) in this domain to rise. Consequently, CMOs need to continue to upgrade their capabilities and infrastructure to keep pace with the evolving product development landscape.

Scope of the Report

The “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030” report features a detailed study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications. The study includes in-depth analyses, highlighting the capabilities of service providers engaged in this domain. In addition to other elements, it includes:

  • A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications. It features information on the year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with their locations (country-wise), and regulatory accreditations and certifications received by them, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites, and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, scale-up, fill/finish, downstream processing, regulatory support, data analytics and reporting, and others), type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications, and others), type of purification method(s) used (desalting, cartridge purification, HPLC, ion exchange purification, PAGE, and others), and compliance to cGMP standards.
  • A company competitiveness analysis, highlighting prominent oligonucleotide manufacturers for research and diagnostic, and therapeutic applications, based on supplier strength (which was calculated by considering the size of employee base of a company and its experience in this field) and service strength (quantified based on scale of operation, expertise in manufacturing different types of oligonucleotides, type of offering, type of manufacturing service(s) offered, type of modification(s) offered, type of purification method(s) used, compliance to cGMP standards, as well as number and location of manufacturing facilities).
  • Elaborate profiles of key players that offer a diverse range of capabilities for custom synthesis, modification and purification of oligonucleotides for use in research and diagnostic, and therapeutic applications. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, details on partnerships, recent developments (expansions), and awards received by the firm, as well as an informed future outlook. 
  • An analysis of the various partnerships pertaining to oligonucleotide manufacturing, which have been established since 2014, based on several parameters, such as the year of partnership, type of partnership, type of partner, most active players (in terms of number of partnerships signed), and a geographical analysis.
  • An analysis of the various expansion initiatives undertaken by service providers engaged in this domain, in order to augment their respective oligonucleotide manufacturing capabilities, over the period 2014-2019, taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation (preclinical, clinical and commercial), application (research and manufacturing operations), and location of manufacturing facility. 
  • A detailed analysis of completed, ongoing and planned clinical research studies of various oligonucleotide-based drug products, highlighting prevalent trends across several relevant parameters, such as trial registration year, phase of development, type of oligonucleotide, current trial recruitment status, study focus area, key therapeutic areas (in terms of number of trials undertaken / conducted), enrolled patient population and trial location, and leading industry and non-industry players (in terms of number of trials undertaken / conducted).
  • An estimate of the overall, installed capacity for manufacturing oligonucleotides based on data reported by industry stakeholders in the public domain; it highlights the distribution of available oligonucleotide synthesis capacity on the basis of company size (small, mid-sized, and large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia-Pacific and rest of the world).
  • An informed estimate of the annual commercial demand for oligonucleotide-based drug products (in grams), taking into account the marketed oligonucleotide products; the analysis takes into consideration the target patient population, dosing frequency and dose strength, of the aforementioned products. The annual clinical demand for oligonucleotide-based drug products was also estimated, taking into account ongoing and planned clinical trials.
  • A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing custom synthesis, modification and purification services for oligonucleotides.

One of the key objectives of this report was to evaluate the current opportunity and the future potential within the oligonucleotide synthesis, modification and purification services market, over the coming decade. Based on various parameters, such as anticipated growth in number of oligonucleotide-focused projects, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] application (research and diagnostic, and therapeutic applications), [B] type of oligonucleotide manufactured (antisense oligonucleotides, siRNA, miRNA, and others), [C] scale of operation (preclinical / clinical, and commercial), [D] company size (small, mid-sized, and large companies), [E] key therapeutic areas (oncological disorders, eye disorders, metabolic disorders, autoimmune disorders, and other therapeutic areas), and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). To account for the uncertainties associated with the growth of the oligonucleotide synthesis, modification and purification services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions presented in this study were influenced by inputs (through an industry-wide survey) of several key players in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals:

  • Tobias Pohlmann (Founder and Managing Director, BianoScience)
  • Joachim Bertram (Chief Scientific Officer and Managing Director, IBA Life Sciences)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading manufacturers of oligonucleotides for use in research, diagnostic and therapeutic applications?
  • What are the preferred custom synthesis, modification and purification methods used for oligonucleotides?
  • What are the key challenges faced by oligonucleotide manufacturers?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What are the recent expansion initiatives undertaken by service providers within this domain? 
  • What is the annual clinical and commercial demand for oligonucleotides?
  • What is the current, installed manufacturing capacity for oligonucleotides?
  • What percentage of oligonucleotide manufacturing operations are outsourced to service providers?
  • What are the opportunities in emerging markets for oligonucleotide manufacturing?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to oligonucleotide manufacturing?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the oligonucleotide synthesis, modification and purification services market in the mid to long term.

Chapter 3 presents a general introduction to oligonucleotides, featuring information on the oligonucleotide-based products available in the market. Further, it features a detailed discussion on different steps involved in the custom synthesis, chemical modification and purification of oligonucleotides, along with information on the key challenges that are currently associated with this market. In addition, the chapter includes a brief discussion on the need for outsourcing within the oligonucleotides market. Further, it includes a list of commonly outsourced oligonucleotide synthesis, modification and purification operations, and highlights the key factors that need to be considered while selecting a service provider. The chapter concludes with a discussion on the key growth drivers and roadblocks related to oligonucleotide manufacturing, as well as upcoming trends in this field.

Chapter 4 provides a detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic applications. The chapter features information on the year of establishment, company size, scale of operation (small, medium, and large), location of headquarters, number of manufacturing facilities, along with their locations (country-wise), and regulatory accreditations and certifications received by them, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites, and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, scale-up, fill/finish, downstream processing, regulatory support, data analytics and reporting, and others), type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications, and others), type of purification method(s) used (desalting, cartridge purification, HPLC, ion exchange purification, PAGE, and others), and compliance to cGMP standards. 

Chapter 5 provides a detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on therapeutic applications. The chapter features information on the year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with their locations (country-wise), and regulatory accreditations and certifications received by them, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites, and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, scale-up, fill/finish, downstream processing, regulatory support, data analytics and reporting, and others), type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications, and others), type of purification method(s) used (desalting, cartridge purification, HPLC, ion exchange purification, PAGE, and others), and compliance to cGMP standards.

Chapter 6 features an insightful company competitiveness analysis of oligonucleotide manufacturers for research and diagnostic applications, based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (which was calculated by considering the size of employee base of a company and its experience in this field) and service strength (quantified based on scale of operation, expertise in manufacturing different types of oligonucleotides, type of offering, type of manufacturing service(s) offered, type of modification(s) offered, type of purification method(s) used, compliance to cGMP standards, as well as number and location of manufacturing facilities). 

Chapter 7 features an insightful company competitiveness analysis of oligonucleotide manufacturers for therapeutic applications, based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (which was calculated by considering the size of employee base of a company and its experience in this field) and service strength (quantified based on scale of operation, expertise in manufacturing different types of oligonucleotides, type of offering, type of manufacturing service(s) offered, type of modification(s) offered, type of purification method(s) used, compliance to cGMP standards, as well as number and location of manufacturing facilities).

Chapter 8 includes elaborate profiles of key industry players (shortlisted on the basis of company competitiveness analysis scores) that offer a diverse range of capabilities for the custom synthesis, modification and purification of oligonucleotides for use in research and diagnostic applications. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, details on partnerships, recent developments (expansions), and awards received by the firm, as well as an informed future outlook.

Chapter 9 includes elaborate profiles of key industry players (shortlisted on the basis of company competitiveness analysis scores) that offer a diverse range of capabilities for the custom synthesis, modification and purification of oligonucleotides for use in therapeutic applications. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, details on partnerships, recent developments (expansions), and awards received by the firm, as well as an informed future outlook.

Chapter 10 features an elaborate analysis of the various partnerships and collaborations that have been inked amongst players in this domain, in the time period 2014-2019. It provides a brief description on the various types of partnership models (which include asset purchase agreements, distribution agreements, manufacturing agreements, mergers / acquisitions, product development agreements, R&D agreements, service alliances, and others) that have been adopted by stakeholders in this domain. Further, it includes analyses based on the year of agreement, type of partner, and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 11 presents detailed analysis on the various expansion initiatives undertaken by service providers engaged in this domain, in order to augment their respective oligonucleotide manufacturing capabilities, over the period 2014-2019. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion, and new facility), scale of operation (preclinical, clinical and commercial), application (research and manufacturing operations), and location of manufacturing facility. 

Chapter 12 provides a detailed analysis of completed, ongoing and planned clinical research studies of various oligonucleotide-based drug products, highlighting prevalent trends across several relevant parameters, such as trial registration year, phase of development, type of oligonucleotide, current trial recruitment status, study focus area, key therapeutic areas (in terms of number of trials undertaken / conducted), enrolled patient population and trial location, and leading industry and non-industry players (in terms of number of trials undertaken / conducted).

Chapter 13 features a detailed analysis of the global / regional capacity of manufacturers that are engaged in the synthesis of oligonucleotides. The analysis takes into consideration the individual manufacturing capacities of various stakeholders (small, mid-sized, and large manufacturers) in the market, using data from both secondary and primary research. It also examines the likely distribution of the global oligonucleotide manufacturing capacity available across different types of companies (small, mid-sized, and large manufacturers), scales of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia-Pacific, and rest of the world).

Chapter 14 features a detailed estimate of the annual demand for oligonucleotide-based drug products (in grams), offering an informed opinion on the required scale of supply (in terms of oligonucleotide synthesis services). In order to estimate the annual commercial demand, we considered the marketed oligonucleotide products; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for oligonucleotide-based drug products was also estimated, taking into account the ongoing and planned clinical trials. 

Chapter 15 presents an insightful market forecast analysis, highlighting the likely growth of the oligonucleotide synthesis, modification and purification services market, till 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] application (research and diagnostic, and therapeutic applications), [B] type of oligonucleotide manufactured (antisense oligonucleotides, siRNA, miRNA, and others), [C] scale of operation (preclinical / clinical, and commercial), [D] company size (small, mid-sized, and large companies), [E] key therapeutic areas (oncological disorders, eye disorders, metabolic disorders, autoimmune disorders, and other therapeutic areas), and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of oligonucleotide synthesis, modification and purification services market, under a detailed SWOT framework.

Chapter 17 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the oligonucleotide synthesis, modification and purification services market.

Chapter 18 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Tobias Pohlmann (Founder and Managing Director, BianoScience) and Joachim Bertram (Chief Scientific Officer and Managing Director, IBA Life Sciences).

Chapter 19 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of this market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of oligonucleotide synthesis, modification and purification service providers. 

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures provided in the report. 

Chapter 21 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Overview of Oligonucleotide-based Products
3.3. Types of Oligonucleotides
3.3.1. Antisense Oligonucleotides
3.3.2. Aptamers
3.3.3. miRNA
3.3.4. shRNA
3.3.5. siRNA
3.3.6. Other Oligonucleotides

3.4. Custom Synthesis of Oligonucleotides
3.4.1. Process Development and Characterization
3.4.2. Analytical Method Development
3.4.3. Method Validation and Testing
3.4.4. Quality Control and Quality Assurance
3.4.5. Challenges Associated with Custom Synthesis of Oligonucleotides

3.5. Chemical Modification of Oligonucleotides
3.5.1. Backbone Modification
3.5.2. Sugar Ring Modification

3.6. Purification of Oligonucleotides
3.6.1. Desalting
3.6.2. Cartridge Purification
3.6.3. Polyacrylamide Gel Electrophoresis (PAGE)
3.6.4. High Performance Liquid Chromatography (HPLC)

3.7. Outsourcing Oligonucleotide Manufacturing
3.7.1. Need for Outsourcing
3.7.2. Commonly Outsourced Operations
3.7.3. Advantages of Outsourcing Manufacturing Operations
3.7.4. Guidelines for Selecting a Service Provider
3.8. Growth Drivers and Roadblocks to Oligonucleotide Manufacturing
3.9. Recent Developments and Upcoming Trends

4. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
4.1. Chapter Overview
4.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Application
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Geographical Location
4.2.6. Analysis by Location of Manufacturing Facilities
4.2.7. Analysis by Regulatory Accreditations / Certifications
4.2.8. Analysis by Type of Oligonucleotide Manufactured
4.2.9. Analysis by Type of Offering
4.2.10. Analysis by Type of Manufacturing Service(s) Offered
4.2.11. Analysis by Type of Modification(s) Offered
4.2.12. Analysis by Type of Purification Method(s) Used
4.2.13. Analysis by Compliance to cGMP Standards

5. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)
5.1. Chapter Overview
5.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Geographical Location
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by Regulatory Accreditations / Certifications
5.2.7. Analysis by Type of Oligonucleotide Manufactured
5.2.8. Analysis by Type of Offering
5.2.9. Analysis by Type of Manufacturing Service(s) Offered
5.2.10. Analysis by Type of Modification(s) Offered
5.2.11. Analysis by Type of Purification Method(s) Used
5.2.12. Analysis by Compliance to cGMP Standards

6. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications
6.3.1. Oligonucleotide Manufacturers in North America
6.3.2. Oligonucleotide Manufacturers in Europe
6.3.3. Oligonucleotide Manufacturers in Asia-Pacific

7. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)
7.1. Chapter Overview
7.2. Key Assumptions and Methodology
7.3. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Therapeutic Applications
7.3.1. Oligonucleotide Manufacturers in North America
7.3.2. Oligonucleotide Manufacturers in Europe
7.3.3. Oligonucleotide Manufacturers in Asia-Pacific

8. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
8.1. Chapter Overview
8.2. Ajinomoto Bio-Pharma Services
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Manufacturing Facilities and Capabilities
8.2.4. Recent Developments and Future Outlook

8.3. Integrated DNA Technologies
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Manufacturing Facilities and Capabilities
8.3.4. Recent Developments and Future Outlook

8.4. Kaneka Eurogentec
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Manufacturing Facilities and Capabilities
8.4.4. Recent Developments and Future Outlook

8.5. LGC Biosearch Technologies
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Manufacturing Facilities and Capabilities
8.5.4. Recent Developments and Future Outlook

8.6. Microsynth
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Manufacturing Facilities and Capabilities
8.6.4. Recent Developments and Future Outlook

8.7. Sigma Aldrich
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Service Portfolio
8.7.4. Manufacturing Facilities and Capabilities
8.7.5. Recent Developments and Future Outlook

8.8. Thermo Fisher Scientific
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Service Portfolio
8.8.4. Manufacturing Facilities and Capabilities
8.8.5. Recent Developments and Future Outlook

9. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)
9.1. Chapter Overview
9.2. Agilent Technologies
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service Portfolio
9.2.4. Manufacturing Facilities and Capabilities
9.2.5. Recent Developments and Future Outlook

9.3. BioSpring
9.3.1. Company Overview
9.3.2. Service Portfolio
9.3.3. Manufacturing Facilities and Capabilities
9.3.4. Recent Developments and Future Outlook

9.4. CordenPharma
9.4.1. Company Overview
9.4.2. Service Portfolio
9.4.3. Manufacturing Facilities and Capabilities
9.4.4. Recent Developments and Future Outlook

9.5. Nitto Denko Avecia
9.5.1. Company Overview
9.5.2. Service Portfolio
9.5.3. Manufacturing Facilities and Capabilities
9.5.4. Recent Developments and Future Outlook

9.6. TriLink Biotechnologies
9.6.1. Company Overview
9.6.2. Service Portfolio
9.6.3. Manufacturing Facilities and Capabilities
9.6.4. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Oligonucleotide Manufacturers: Recent Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partner
10.3.4. Most Active Players: Analysis by Number of Partnerships
10.3.5. Geographical Analysis
10.3.5.1. Most Active Players: Geographical Distribution by Number of Partnerships
10.3.5.2. Intercontinental and Intracontinental Agreements

11. RECENT EXPANSIONS
11.1. Chapter Overview
11.2. Oligonucleotide Manufacturers: Recent Expansions
11.2.1. Analysis by Year of Expansion
11.2.2. Analysis by Type of Expansion
11.2.3. Analysis by Application
11.2.4. Analysis by Location of Facility
11.2.5. Analysis by Expanded Facility Area
11.2.6. Analysis by Expanded Scale of Operation
11.3.7. Most Active Players: Analysis by Number of Expansions
11.3.8. Geographical Analysis
11.3.8.1. Continent-wise Distribution
11.3.8.2. Country-wise Distribution

12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Clinical Trial Analysis: Oligonucleotide-based Drug Products
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Phase of Development
12.3.3. Analysis by Type of Oligonucleotide
12.3.4. Analysis by Trial Recruitment Status
12.3.5. Analysis by Trial Focus Area
12.3.6. Analysis by Target Therapeutic Area
12.3.7. Geographical Analysis by Number of Clinical Trials
12.3.8. Geographical Analysis by Enrolled Patient Population
12.3.9. Analysis by Type of Sponsor / Collaborator
12.3.10. Most Active Players: Analysis by Number of Registered Trials
12.3.11. Competitive Benchmarking (Clinical Research): Active Industry Player

13. CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Oligonucleotide Manufacturers: Global, Installed Capacity
13.3.1. Analysis by Company Size
13.3.2. Analysis by Scale of Operation
13.3.3. Analysis by Location of Manufacturing Facility
13.4. Concluding Remarks

14. DEMAND ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Commercial Demand for Oligonucleotide Manufacturing
14.3.1. Analysis by Target Therapeutic Area
14.3.2. Analysis by Scale of Operation
14.3.3. Analysis by Geography

14.4. Global Clinical Demand for Oligonucleotide Manufacturing
14.4.1. Analysis by Target Therapeutic Area
14.4.2. Analysis by Scale of Operation
14.4.3. Analysis by Geography

14.5. Demand and Supply Analysis

15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Forecast Methodology
15.3. Overall Oligonucleotide Manufacturing Market, 2020-2030

15.4. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Application
15.4.1. Oligonucleotide Manufacturing Market Focused on Research and Diagnostic Applications, 2020-2030
15.4.2. Oligonucleotide Manufacturing Market Focused on Therapeutic Applications, 2020-2030

15.5. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Type of Oligonucleotide Manufactured
15.5.1. Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2020-2030
15.5.2. Oligonucleotide Manufacturing Market for siRNA, 2020-2030
15.5.3. Oligonucleotide Manufacturing Market for miRNA, 2020-2030
15.5.4. Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2020-2030

15.6. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Scale of Operation
15.6.1. Oligonucleotide Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030
15.6.2. Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2020-2030

15.7. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Company Size
15.7.1. Oligonucleotide Manufacturing Market for Small Companies, 2020-2030
15.7.2. Oligonucleotide Manufacturing Market for Mid-sized Companies, 2020-2030
15.7.3. Oligonucleotide Manufacturing Market for Large Companies, 2020-2030

15.8. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Target Therapeutic Area
15.8.1. Oligonucleotide Manufacturing Market for Oncological Disorders, 2020-2030
15.8.2. Oligonucleotide Manufacturing Market for Eye Disorders, 2020-2030
15.8.3. Oligonucleotide Manufacturing Market for Metabolic Disorders, 2020-2030
15.8.4. Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2020-2030
15.8.5. Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2020-2030

15.9. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Geography
15.9.1. Oligonucleotide Manufacturing Market in North America, 2020-2030
15.9.2. Oligonucleotide Manufacturing Market in Europe, 2020-2030
15.9.3. Oligonucleotide Manufacturing Market in Asia-Pacific, 2020-2030
15.9.4. Oligonucleotide Manufacturing Market in Rest of the World, 2020-2030

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Comparison of SWOT Factors

17. SURVEY ANALYSIS
17.1. Chapter Overview
17.2. Overview of Respondents
17.2.1. Seniority Level of Respondents

17.3. Survey Insights
17.3.1. Type of Offering
17.3.2. Application
17.3.3. Manufacturing Capacity
17.3.4. Location of Manufacturing Facilities
17.3.5. Extent of Outsourcing
17.3.6. Current Market Opportunity

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. BianoScience
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Tobias Pohlmann, Founder and Managing Director

18.3. IBA Life Sciences
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Joachim Bertram, Chief Scientific Officer and Managing Director

19. CONCLUDING REMARKS
19.1. Chapter Overview
19.2. Key Takeaways

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Classification of Oligonucleotides 
Figure 3.2 Steps Involved in the Manufacturing of Oligonucleotides
Figure 3.3 Types of Chemical Modifications of Oligonucleotides
Figure 3.4 Types of Purification Methods Used for Oligonucleotides
Figure 3.5 Types of Standalone Service Providers
Figure 3.6 Services Offered by Oligonucleotide Manufacturers
Figure 3.7 Commonly Outsourced Operations
Figure 3.8 Guidelines for Selecting a Service Provider
Figure 3.9 Growth Drivers and Roadblocks to Oligonucleotide Manufacturing
Figure 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Figure 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Figure 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Application
Figure 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Figure 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment, Company Size and Scale of Operation
Figure 4.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Region-wise)
Figure 4.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Country-wise)
Figure 4.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 4.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 4.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
Figure 4.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 4.12 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
Figure 4.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
Figure 4.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Modification(s) Offered
Figure 4.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method(s) Used
Figure 4.16 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Compliance to cGMP Standards
Figure 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Figure 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Figure 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Figure 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment, Company Size and Scale of Operation
Figure 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Region-wise)
Figure 5.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Country-wise)
Figure 5.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 5.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 5.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
Figure 5.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 5.11 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
Figure 5.12 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service(s) Offered
Figure 5.13 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Modification(s) Offered
Figure 5.14 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method(s) Used
Figure 5.15 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Compliance to cGMP Standards
Figure 6.1 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in North America
Figure 6.2 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in Europe
Figure 6.3 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in Asia-Pacific
Figure 7.1 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Therapeutic Applications in North America
Figure 7.2 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Therapeutic Applications in Europe
Figure 7.3 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Therapeutic Applications in Asia-Pacific
Figure 8.1 Sigma Aldrich: Net Revenues, FY 2015 - H1 FY 2019 (USD Million)
Figure 8.2 Sigma Aldrich: Distribution of Net Revenues by Business Segment, FY 2018 (USD Million)
Figure 8.3 Thermo Fisher Scientific: Net Revenues, FY 2014 - FY 2019 (USD Billion)
Figure 8.4 Thermo Fisher Scientific: Distribution of Net Revenues by Business Segment, FY 2019 (USD Billion)
Figure 9.1 Agilent Technologies: Net Revenues, FY 2015 - FY 2018 (USD Billion)
Figure 9.2 Agilent Technologies: Distribution of Net Revenues by Business Segment, FY 2018 (USD Billion)
Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership, 2014-2019
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2014-2019 
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.5 Most Active Players: Distribution by Number of Partnerships
Figure 10.6 Most Active Players: Geographical Distribution by Number of Partnerships 
Figure 10.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 11.1 Recent Expansions: Distribution by Year of Expansion, 2014-2019
Figure 11.2 Recent Expansions: Distribution by Type of Expansion
Figure 11.3 Recent Expansions: Year-wise Trend by Type of Expansion, 2014-2019
Figure 11.4 Recent Expansions: Distribution by Application
Figure 11.5 Recent Expansions: Distribution by Location of Facility
Figure 11.6 Recent Expansions: Distribution by Type of Expansion and Location of Facility
Figure 11.7 Recent Expansions: Distribution by Type of Expansion and Application
Figure 11.8 Recent Expansions: Distribution by Expanded Facility Area (sq ft)
Figure 11.9 Recent Expansions: Distribution by Expanded Scale of Operation
Figure 11.10 Most Active Players: Distribution by Number of Expansions
Figure 11.11 Recent Expansions: Distribution by Geography
Figure 11.12 Recent Expansions: Year-wise Trend by Geography, 2014-2019
Figure 12.1 Clinical Trials: Distribution by Trial Registration Year, Pre-2012-2019
Figure 12.2 Clinical Trials: Distribution by Phase of Development
Figure 12.3 Clinical Trials: Distribution by Type of Oligonucleotide
Figure 12.4 Clinical Trials: Distribution by Trial Registration Year and Type of Oligonucleotide, Pre-2012-2019
Figure 12.5 Clinical Trials: Distribution by Trial Recruitment Status
Figure 12.6 Clinical Trials: Distribution by Trial Registration Year and Recruitment Status, Pre-2012-2019
Figure 12.7 Clinical Trials: Popular Keywords
Figure 12.8 Clinical Trials: Distribution by Target Therapeutic Area
Figure 12.9 Clinical Trials: Distribution by Trial Registration Year and Target Therapeutic Area, Pre-2012-2019
Figure 12.10 Clinical Trials: Geographical Distribution by Number of Clinical Trials
Figure 12.11 Clinical Trials: Geographical Distribution by Trial Registration Year, Pre-2012-2019 
Figure 12.12 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Figure 12.13 Clinical Trials: Cumulative Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2012-2019
Figure 12.14 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 12.15 Clinical Trials: Distribution by Type of Sponsor / Collaborator and Target Therapeutic Area
Figure 12.16 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 12.17 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.18 Clinical Trials: Distribution by Trial Registration Year and Most Active Industry Players, 2014-2019
Figure 12.19 Clinical Trials: Benchmarking by Number of Trials across Key Therapeutic Areas
Figure 13.1 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 13.2 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Grams)
Figure 13.3 Global Oligonucleotide Manufacturing Capacity: Distribution by Scale of Operation (Grams)
Figure 13.4 Global Oligonucleotide Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Grams)
Figure 14.1 Global, Commercial Demand for Oligonucleotide Manufacturing (Grams)
Figure 14.2 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
Figure 14.3 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
Figure 14.4 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
Figure 14.5 Global, Clinical Demand for Oligonucleotide Manufacturing (Grams)
Figure 14.6 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
Figure 14.7 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
Figure 14.8 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
Figure 14.8 Global Oligonucleotide Manufacturing: Demand and Supply
Figure 15.1 Overall Oligonucleotide Manufacturing Market, 2020-2030 (USD Million)
Figure 15.2 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Application (USD Million)
Figure 15.3 Oligonucleotide Manufacturing Market Focused on Research and Diagnostic Applications, 2020-2030 (USD Million)
Figure 15.4 Oligonucleotide Manufacturing Market Focused on Therapeutic Applications, 2020-2030 (USD Million)
Figure 15.5 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Type of Oligonucleotide Manufactured (USD Million)
Figure 15.6 Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2020-2030 (USD Million)
Figure 15.7 Oligonucleotide Manufacturing Market for siRNA, 2020-2030 (USD Million)
Figure 15.8 Oligonucleotide Manufacturing Market for miRNA, 2020-2030 (USD Million)
Figure 15.9 Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2020-2030 (USD Million)
Figure 15.10 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Million)
Figure 15.11 Oligonucleotide Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
Figure 15.12 Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Million)
Figure 15.13 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Company Size (USD Million)
Figure 15.14 Oligonucleotide Manufacturing Market for Small Companies, 2020-2030 (USD Million)
Figure 15.15 Oligonucleotide Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Million)
Figure 15.16 Oligonucleotide Manufacturing Market for Large Companies, 2020-2030 (USD Million)
Figure 15.17 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area (USD Million)
Figure 15.18 Oligonucleotide Manufacturing Market for Oncological Disorders, 2020-2030 (USD Million)
Figure 15.19 Oligonucleotide Manufacturing Market for Eye Disorders, 2020-2030 (USD Million)
Figure 15.20 Oligonucleotide Manufacturing Market for Metabolic Disorders, 2020-2030 (USD Million)
Figure 15.21 Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2020-2030 (USD Million)
Figure 15.22 Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2020-2030 (USD Million)
Figure 15.23 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Geography (USD Million)
Figure 15.24 Oligonucleotide Manufacturing Market in North America, 2020-2030 (USD Million)
Figure 15.25 Oligonucleotide Manufacturing Market in Europe, 2020-2030 (USD Million)
Figure 15.26 Oligonucleotide Manufacturing Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 15.27 Oligonucleotide Manufacturing Market in Rest of the World, 2020-2030 (USD Million)
Figure 16.1 Oligonucleotide Manufacturing Market: SWOT Analysis
Figure 16.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 17.1 Survey Insights: Distribution by Type of Organization
Figure 17.2 Survey Insights: Distribution by Location of Organization
Figure 17.3 Survey Insights: Distribution by Seniority Level
Figure 17.4 Survey Insights: Distribution by Type of Offering
Figure 17.5 Survey Insights: Distribution by Application
Figure 17.6 Survey Insights: Distribution by Location of Manufacturing Facilities
Figure 17.7 Survey Insights: Distribution by Extent of Outsourcing
Figure 17.8 Survey Insights: Distribution by Current Market Opportunity

List Of Tables

Table 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
Table 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
Table 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
Table 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Manufacturing Service(s) Offered
Table 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Modification(s) Offered, Type of Purification Method(s) Used and Compliance to cGMP Standards
Table 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
Table 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
Table 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
Table 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Manufacturing Service(s) Offered
Table 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Modification(s) Offered, Type of Purification Method(s) Used and Compliance to cGMP Standards
Table 8.1 Ajinomoto Bio-Pharma Services: Key Highlights
Table 8.2 Ajinomoto Bio-Pharma Services: Service Portfolio
Table 8.3 Ajinomoto Bio-Pharma Services: Manufacturing Facilities and Capabilities
Table 8.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 8.5 Integrated DNA Technologies: Key Highlights
Table 8.6 Integrated DNA Technologies: Service Portfolio
Table 8.7 Integrated DNA Technologies: Manufacturing Facilities and Capabilities
Table 8.8 Integrated DNA Technologies: Recent Developments and Future Outlook
Table 8.9 Kaneka Eurogentec: Key Highlights
Table 8.10 Kaneka Eurogentec: Service Portfolio
Table 8.11 Kaneka Eurogentec: Manufacturing Facilities and Capabilities
Table 8.12 Kaneka Eurogentec: Recent Developments and Future Outlook
Table 8.13 LGC, Biosearch Technologies: Key Highlights
Table 8.14 LGC, Biosearch Technologies: Service Portfolio
Table 8.15 LGC, Biosearch Technologies: Manufacturing Facilities and Capabilities
Table 8.16 LGC, Biosearch Technologies: Recent Developments and Future Outlook
Table 8.17 Microsynth: Key Highlights
Table 8.18 Microsynth: Service Portfolio
Table 8.19 Microsynth: Manufacturing Facilities and Capabilities
Table 8.20 Microsynth: Recent Developments and Future Outlook
Table 8.21 Sigma Aldrich: Key Highlights
Table 8.22 Sigma Aldrich: Service Portfolio
Table 8.23 Sigma Aldrich: Manufacturing Facilities and Capabilities
Table 8.24 Sigma Aldrich: Recent Developments and Future Outlook
Table 8.25 Thermo Fisher Scientific: Key Highlights
Table 8.26 Thermo Fisher Scientific: Service Portfolio
Table 8.27 Thermo Fisher Scientific: Manufacturing Facilities and Capabilities
Table 8.28 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.1 Agilent Technologies: Key Highlights
Table 9.2 Agilent Technologies: Service Portfolio
Table 9.3 Agilent Technologies: Manufacturing Facilities and Capabilities
Table 9.4 Agilent Technologies: Recent Developments and Future Outlook
Table 9.5 BioSpring: Key Highlights
Table 9.6 BioSpring: Service Portfolio
Table 9.7 BioSpring: Manufacturing Facilities and Capabilities
Table 9.8 BioSpring: Recent Developments and Future Outlook
Table 9.9 CordenPharma: Key Highlights
Table 9.10 CordenPharma: Service Portfolio
Table 9.11 CordenPharma: Manufacturing Facilities and Capabilities
Table 9.12 CordenPharma: Recent Developments and Future Outlook
Table 9.13 Nitto Denko Avecia: Key Highlights
Table 9.14 Nitto Denko Avecia: Service Portfolio
Table 9.15 Nitto Denko Avecia: Manufacturing Facilities and Capabilities
Table 9.16 Nitto Denko Avecia: Recent Developments and Future Outlook
Table 9.17 TriLink Biotechnologies: Key Highlights
Table 9.18 TriLink Biotechnologies: Service Portfolio
Table 9.19 TriLink Biotechnologies: Manufacturing Facilities and Capabilities
Table 9.20 TriLink Biotechnologies: Recent Developments and Future Outlook
Table 10.1 Oligonucleotide Manufacturers: List of Partnerships, 2014-2019
Table 10.2 Most Active Players: Geographical Distribution by Type of Partnership Model
Table 11.1 Oligonucleotide Manufacturers: List of Expansions, 2014-2019
Table 13.1 Global Oligonucleotide Manufacturing Capacity: Average Capacity based on Company Size (Sample Data Set)
Table 13.2 Global Oligonucleotide Manufacturing Capacity: Average Capacity based on Scale of Operation (Sample Data Set)
Table 13.3 Global Oligonucleotide Manufacturing Capacity: Average Capacity based on Location of Company (Sample Data Set)
Table 17.1 Survey Insights: Overview of Respondents
Table 17.2 Survey Insights: Seniority Level of Respondents
Table 17.3 Survey Insights: Type of Offering
Table 17.4 Survey Insights: Application
Table 17.5 Survey Insights: Oligonucleotide Manufacturing Capacity
Table 17.6 Survey Insights: Number and Location of Manufacturing Facilities
Table 17.7 Survey Insights: Extent of Outsourcing
Table 17.8 Survey Insights: Current Market Opportunity (USD Million)
Table 18.1 BianoScience: Key Highlights
Table 18.2 IBA Life Sciences: Key Highlights
Table 19.1 Oligonucleotide Manufacturing Market: Key Takeaways
Table 20.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Table 20.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Table 20.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Application
Table 20.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Table 20.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Region-wise)
Table 20.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Country-wise)
Table 20.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
Table 20.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 20.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
Table 20.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
Table 20.12 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
Table 20.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
Table 20.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Modification(s) Offered
Table 20.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method(s) Used
Table 20.16 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Compliance to cGMP Standards
Table 20.17 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Table 20.18 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Table 20.19 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Table 20.20 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Region-wise)
Table 20.21 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Country-wise)
Table 20.22 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
Table 20.23 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 20.24 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
Table 20.25 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
Table 20.26 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
Table 20.27 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service(s) Offered
Table 20.28 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Modification(s) Offered
Table 20.29 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method(s) Used
Table 20.30 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Compliance to cGMP Standards
Table 20.31 Sigma Aldrich: Net Revenues, FY 2015 - H1 FY 2019 (USD Million)
Table 20.32 Sigma Aldrich: Distribution of Net Revenues by Business Segment, FY 2018 (USD Million)
Table 20.33 Thermo Fisher Scientific: Net Revenues, FY 2014 - FY 2019 (USD Billion)
Table 20.34 Thermo Fisher Scientific: Distribution of Net Revenues by Business Segment, FY 2019 (USD Billion)
Table 20.35 Agilent Technologies: Net Revenues, FY 2015 - FY 2018 (USD Billion)
Table 20.36 Agilent Technologies: Distribution of Net Revenues by Business Segment, FY 2018 (USD Billion)
Table 20.37 Partnerships and Collaborations: Distribution by Year of Partnership, 2014-2019
Table 20.38 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.39 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2014-2019 
Table 20.40 Partnerships and Collaborations: Distribution by Type of Partner
Table 20.41 Most Active Players: Distribution by Number of Partnerships
Table 20.42 Most Active Players: Geographical Distribution by Number of Partnerships 
Table 20.43 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 20.44 Recent Expansions: Distribution by Year of Expansion, 2014-2019
Table 20.45 Recent Expansions: Distribution by Type of Expansion
Table 20.46 Recent Expansions: Year-wise Trend by Type of Expansion, 2014-2019
Table 20.47 Recent Expansions: Distribution by Application
Table 20.48 Recent Expansions: Distribution by Location of Facility
Table 20.49 Recent Expansions: Distribution by Type of Expansion and Location of Facility
Table 20.50 Recent Expansions: Distribution by Type of Expansion and Application
Table 20.51 Recent Expansions: Distribution by Expanded Facility Area (sq ft)
Table 20.52 Recent Expansions: Distribution by Expanded Scale of Operation
Table 20.53 Most Active Players: Distribution by Number of Expansions
Table 20.54 Recent Expansions: Distribution by Geography
Table 20.55 Recent Expansions: Year-wise Trend by Geography, 2014-2019
Table 20.56 Clinical Trials: Distribution by Trial Registration Year, Pre-2012-2019
Table 20.57 Clinical Trials: Distribution by Phase of Development
Table 20.58 Clinical Trials: Distribution by Type of Oligonucleotide
Table 20.59 Clinical Trials: Distribution by Trial Registration Year and Type of Oligonucleotide, Pre-2012-2019
Table 20.60 Clinical Trials: Distribution by Trial Recruitment Status
Table 20.61 Clinical Trials: Distribution by Trial Registration Year and Recruitment Status, Pre-2012-2019
Table 20.62 Clinical Trials: Distribution by Target Therapeutic Area
Table 20.63 Clinical Trials: Distribution by Trial Registration Year and Target Therapeutic Area, Pre-2012-2019
Table 20.64 Clinical Trials: Geographical Distribution by Number of Clinical Trials
Table 20.65 Clinical Trials: Geographical Distribution by Trial Registration Year, Pre-2012-2019 
Table 20.66 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Table 20.67 Clinical Trials: Cumulative Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2012-2019
Table 20.68 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 20.69 Clinical Trials: Distribution by Type of Sponsor / Collaborator and Target Therapeutic Area
Table 20.70 Most Active Industry Players: Distribution by Number of Registered Trials
Table 20.71 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 20.72 Clinical Trials: Distribution by Trial Registration Year and Most Active Industry Players, 2014-2019
Table 20.73 Clinical Trials: Benchmarking by Number of Trials across Key Therapeutic Areas
Table 20.74 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 20.75 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Grams)
Table 20.76 Global Oligonucleotide Manufacturing Capacity: Distribution by Scale of Operation (Grams)
Table 20.77 Global Oligonucleotide Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Grams)
Table 20.78 Global, Commercial Demand for Oligonucleotide Manufacturing (Grams)
Table 20.79 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
Table 20.80 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
Table 20.81 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
Table 20.82 Global, Clinical Demand for Oligonucleotide Manufacturing (Grams)
Table 20.83 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
Table 20.84 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
Table 20.85 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
Table 20.86 Global Oligonucleotide Manufacturing: Demand and Supply
Table 20.87 Overall Oligonucleotide Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.88 Oligonucleotide Manufacturing Market: Distribution by Application, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.89 Oligonucleotide Manufacturing Market Focused on Research and Diagnostic Applications, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.90 Oligonucleotide Manufacturing Market Focused on Therapeutic Applications, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.91 Oligonucleotide Manufacturing Market: Distribution by Type of Oligonucleotide Manufactured, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.92 Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.93 Oligonucleotide Manufacturing Market for siRNA, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.94 Oligonucleotide Manufacturing Market for miRNA, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.95 Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.96 Oligonucleotide Manufacturing Market: Distribution by Scale of Operation, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.97 Oligonucleotide Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.98 Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.99 Oligonucleotide Manufacturing Market: Distribution by Company Size, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.100 Oligonucleotide Manufacturing Market for Small Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.101 Oligonucleotide Manufacturing Market for Mid-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.102 Oligonucleotide Manufacturing Market for Large Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.103 Oligonucleotide Manufacturing Market: Distribution by Target Therapeutic Area, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.104 Oligonucleotide Manufacturing Market for Oncological Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.105 Oligonucleotide Manufacturing Market for Eye Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.106 Oligonucleotide Manufacturing Market for Metabolic Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.107 Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.108 Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.109 Oligonucleotide Manufacturing Market: Distribution by Geography, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.110 Oligonucleotide Manufacturing Market in North America, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.111 Oligonucleotide Manufacturing Market in Europe, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.112 Oligonucleotide Manufacturing Market in Asia-Pacific, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.113 Oligonucleotide Manufacturing Market in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.114 Survey Insights: Distribution by Type of Organization
Table 20.115 Survey Insights: Distribution by Location of Organization
Table 20.116 Survey Insights: Distribution by Seniority Level
Table 20.117 Survey Insights: Distribution by Type of Offering
Table 20.117 Survey Insights: Distribution by Application
Table 20.118 Survey Insights: Distribution by Location of Manufacturing Facilities
Table 20.119 Survey Insights: Distribution by Extent of Outsourcing
Table 20.120 Survey Insights: Distribution by Current Market Opportunity

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. A/Z
  2. Aarhus University
  3. Abacus dx
  4. Abbott
  5. AbbVie
  6. ACGT 
  7. Achieve Life Sciences
  8. Aegera Therapeutics
  9. Aeras
  10. Agilent Technologies
  11. AITbiotech
  12. Ajinomoto Bio-Pharma Services
  13. Akcea Therapeutics
  14. Allele Biotechnology & Pharmaceuticals
  15. Allergan
  16. Allianz BioInnovation
  17. Alnylam Pharmaceuticals
  18. Alta Bioscience
  19. AM Chemicals
  20. Amgen
  21. AmpTec
  22. Anesiva
  23. AnGes
  24. Applied Biological Materials
  25. Aptose Biosciences
  26. Arbutus Biopharma
  27. Archemix
  28. Argonaut Manufacturing Services
  29. Arrowhead Pharmaceuticals
  30. AstraZeneca
  31. ATDBio
  32. ATZ Labs
  33. Averica Discovery Services
  34. Avrio Biopharmaceuticals
  35. Axolabs
  36. Bachem
  37. Band Therapeutics
  38. Baylor College of Medicine
  39. Benitec Biopharma
  40. Berry & Associates
  41. BianoScience
  42. Bio Basic
  43. BioAutomation
  44. Biolegio
  45. BioLineRx
  46. Bioneer
  47. Bio-Path Holdings
  48. Biosearch Technologies
  49. BioServe Biotechnologies
  50. BioSpring
  51. Bio-Synthesis
  52. Boston Children's Hospital
  53. BR Biochem Life Sciences
  54. Bridgen
  55. Brigham and Women's Hospital
  56. Bristol-Myers Squibb
  57. British Columbia Cancer Agency
  58. bts Biotech Trade & Service
  59. Calimmune
  60. Canadian Cancer Trials Group
  61. Cancer Genetics
  62. Celgene
  63. Central Finland Central Hospital
  64. ChemGenes
  65. Co-Diagnostics
  66. CordenPharma
  67. Creative Biogene
  68. CSL Behring
  69. CUSABIO TECHNOLOGY
  70. CyberGene
  71. Daiichi Sankyo
  72. Dalton Pharma Services
  73. Dana-Farber Cancer Institute
  74. Dharmacon
  75. Dicerna Pharmaceuticals
  76. Dizal Pharmaceutical
  77. Duke University
  78. Dynacure
  79. Dynavax Technologies
  80. Eastern Cooperative Oncology Group
  81. Elim Biopharmaceuticals
  82. EMD Serono
  83. Enzon Pharmaceuticals
  84. Eton Bioscience
  85. Eunice Kennedy Shriver National Institute of Child Health and Human Development
  86. Eurofins Genomics
  87. European Organisation for Research and Treatment of Cancer
  88. Expedeon
  89. Eyetech Pharmaceuticals
  90. FGK Clinical Research
  91. Fred Hutchinson Cancer Research Center
  92. FUTUREsynthesis
  93. GCC Biotech
  94. GE Healthcare
  95. Genbiotech
  96. Gene Universal
  97. GeneDesign
  98. Genei Laboratories
  99. GenePharma
  100. General Biosystems
  101. GENERI BIOTECH
  102. GENEWIZ
  103. GeneWorks
  104. GenScript
  105. Genta
  106. Genzyme
  107. George Washington University
  108. Georgetown University
  109. German CLL Study Group
  110. German Federal Ministry of Education and Research
  111. Gradalis
  112. Granzer Regulatory Consulting & Services
  113. Hanugen Therapeutics
  114. Helsinki University Central Hospital
  115. HIV Vaccine Trials Network
  116. Hoffmann-La Roche
  117. Hoosier Cancer Research Network
  118. Huabo Biopharm
  119. i3 Research
  120. IBA Lifesciences
  121. Idera Pharmaceuticals
  122. Imperial College London
  123. Incheon St.Mary's Hospital
  124. Infectious Disease Research Institute
  125. inqaba biotec™
  126. INSYS Therapeutics
  127. Integrated DNA Technologies
  128. International AIDS Vaccine Initiative
  129. Ionis Pharmaceuticals
  130. Irvine Pharmaceutical Services
  131. Isarna Therapeutics
  132. James P. Wilmot Cancer Center
  133. Janssen Research & Development
  134. Johns Hopkins University
  135. Kainuu Central Hospital
  136. Kaneka Eurogentec
  137. Kanta-Hame Central Hospital
  138. KareBay Biochem
  139. Koram Biotech
  140. Kuopio University Hospital
  141. Kymenlaakso Central Hospital Kotka Finland
  142. Lonza
  143. LubioScience
  144. M.D. Anderson Cancer Center
  145. Maastricht University Medical Center
  146. Mario Negri Institute for Pharmacological Research
  147. Mary Crowley Cancer Research
  148. Massachusetts General Hospital
  149. MBC BioLabs
  150. MBiotech
  151. Medigene
  152. MedImmune
  153. Merck
  154. Microsynth
  155. Midland Certified Reagent 
  156. Mikkeli Central Hospital
  157. Mina Alpha
  158. miRagen Therapeutics
  159. Moligo Technologies
  160. National Cancer Institute
  161. National Cancer Institute of Canada – Clinical Trials Group 
  162. National Eye Institute
  163. National Heart, Lung, and Blood Institute
  164. National Institute of Allergy and Infectious Diseases
  165. National Institute of Diabetes and Digestive and Kidney Diseases
  166. National Institutes of Health
  167. National Institutes of Health Clinical Center
  168. Nitto Denko Avecia
  169. Novatia
  170. NOXXON Pharma
  171. NYU Langone Health
  172. NZYTech
  173. Oligomer
  174. OliX Pharmaceuticals
  175. Ophthotech
  176. OPKO Health
  177. Orphan Disease Treatment Institute
  178. Osaka International Cancer Institute 
  179. Osaka Prefectural Hospital Organization
  180. Oulu University Hospital
  181. Pennington Biomedical Research Center
  182. Pfizer
  183. PharmaMar
  184. Pharmaxis
  185. Primetech
  186. ProQR Therapeutics
  187. Quark Pharmaceuticals
  188. Quintara Biosciences
  189. R&D Kanglin Biotech
  190. Radboud University
  191. Regulus Therapeutics
  192. RemeGen
  193. ReNetX Bio
  194. ReproCell
  195. Retina Institute of Hawaii
  196. Retinal Consultants of Arizona
  197. RiboBio
  198. Rockland Immunochemicals
  199. Ruibo Bio-Technology
  200. RXi Pharmaceuticals
  201. Samuel Lunenfeld Research Institute, Mount Sinai Hospital
  202. Sanofi
  203. Santaris Pharma
  204. Sarepta Therapeutics
  205. Satakunta Central Hospital
  206. Scandinavian Gene Synthesis
  207. Science Exchange
  208. Severn Biotech
  209. Shanghai Public Health Clinical Center
  210. Shanghai Zerun Biotechnology
  211. Sierra Oncology
  212. Sigma Aldrich
  213. Silence Therapeutics
  214. Silenseed
  215. Sirna Therapeutics
  216. SomaLogic
  217. ST Pharm
  218. STA Pharmaceuticals
  219. Stanford University
  220. Statens Serum Institut
  221. Sterna Biologicals
  222. Sumitomo Chemical
  223. Sunomix Biosciences
  224. Sylentis
  225. Synbio Technologies
  226. Syngene International
  227. Tacere Therapeutics
  228. TAG Copenhagen
  229. Takara Bio USA
  230. Tampere University Hospital
  231. Tectron
  232. The Medicines Company
  233. The University of Texas Health Science Center at San Antonio
  234. Thermo Fisher Scientific
  235. TIMI Study Group
  236. TriLink Biotechnologies
  237. Tsinghua University
  238. Turku University Hospital
  239. UNC Lineberger Comprehensive Cancer Center
  240. Universitaire Ziekenhuizen Leuven
  241. University of Chicago
  242. University of Michigan Rogel Cancer Center
  243. University of Munich
  244. University of Oxford
  245. University of Pennsylvania
  246. University of Pittsburgh
  247. University of Rochester
  248. University of Toronto
  249. ValueGene
  250. Vivantis Technologies
  251. VWR
  252. Wake Forest University
  253. Wave Life Sciences
  254. Wings Therapeutics
  255. Winthrop University Hospital
  256. Xcelris
  257. ZonMw

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com